


PRODUCT INFORMATION



LE 135

Item No. 14415

CAS Registry No.: 155877-83-1
Formal Name: 4-(7,8,9,10-tetrahydro-5,7,7,10,10-pentamethyl-5H-benzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)-benzoic acid
MF: C₂₉H₃₀N₂O₂
FW: 438.6
Purity: ≥98%
UV/Vis.: λ_{max}: 267, 399 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LE 135 is supplied as a crystalline solid. A stock solution may be made by dissolving the LE 135 in the solvent of choice, which should be purged with an inert gas. LE 135 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of LE 135 in these solvents is approximately 1.1, 12.5, and 5 mg/ml, respectively.

LE 135 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LE 135 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. LE 135 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

LE 135 is a retinoic acid receptor (RAR) antagonist that displays moderate selectivity for RAR β over RAR α (K_s = 0.22 and 1.4 μ M, respectively).^{1,2} LE 135 inhibits retinoic acid-induced transcriptional activation of RAR β (>70% inhibition at 10 μ M), but not RAR α , RAR γ or retinoid X receptor α .¹ It has been shown to inhibit retinoid Am80-induced differentiation of human promyelocytic leukemia cells, HL-60, with an IC₅₀ value of 0.2 μ M.³

References

1. Li, Y., Hashimoto, Y., Agadir, A., *et al.* Identification of a novel class of retinoic acid receptor b-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. *J. Bio. Chem.* **274** (22), 15360-15366 (1999).
2. Eyrolles, L., Kagechika, H., Kawachi, E., *et al.* Retinobenzoic Acids. 6. Retinoid antagonists with a heterocyclic ring. *J. Med. Chem.* **37**(10), 1508-1517 (1994).
3. Umemiya, H., Fukasawa, H., Ebisawa, M., *et al.* Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. *J. Med. Chem.* **40**(26), 4222-4234 (1997).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM